Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 15, Issue 2, Pages 112-120
Publisher
Wiley
Online
2012-08-24
DOI
10.1111/dom.12000
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2013) David Moher ANNALS OF INTERNAL MEDICINE
- DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis
- (2012) Matteo Monami et al. ADVANCES IN THERAPY
- Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus
- (2012) G. Schernthaner et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus
- (2011) Jean Doucet et al. CURRENT MEDICAL RESEARCH AND OPINION
- Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials
- (2011) Matteo Monami et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effects of a long-acting GLP-1 mimetic (PF-04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus
- (2011) S. M. Gustavson et al. DIABETES OBESITY & METABOLISM
- Effect of Exenatide on Inflammatory and Oxidative Stress Markers in Patients with Type 2 Diabetes Mellitus
- (2011) Jin-dan Wu et al. Diabetes Technology & Therapeutics
- Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
- (2011) Gian Paolo Fadini et al. VASCULAR PHARMACOLOGY
- Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines
- (2010) Wataru Takasawa et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease
- (2010) Philip A. Read et al. Circulation-Cardiovascular Imaging
- Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database
- (2010) E. S. Horton et al. DIABETES CARE
- The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1
- (2010) G. P. Fadini et al. DIABETES CARE
- Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
- (2010) A. Schweizer et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- (2010) Joshua J Neumiller et al. PHARMACOTHERAPY
- Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
- (2010) Debora Williams-Herman et al. BMC Endocrine Disorders
- Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events
- (2009) Bo Ahrén BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
- (2009) M. Monami et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments
- (2008) Edward J. Mills et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started